Table 3.

C-index of different models for PFS in the training and validation cohorts.

Models	Training cohort	p †	Validation cohort	p †
ADMAN Model	0.75 (0.69–0.82)	–	0.71 (0.60–0.83)	–
HAP Score	0.62 (0.55–0.71)	0.004	0.55 (0.47–0.70)	0.041
mHAP Score	0.65 (0.58–0.73)	0.014	0.54 (0.40–0.69)	0.033
mHAP-II Score	0.63 (0.55–0.70)	0.002	0.61 (0.48–0.74)	0.080
Six-and-Twelve Score	0.63 (0.56–0.70)	<0.001	0.64 (0.53–0.75)	0.231
Up-to-11 criteria	0.60 (0.53–0.67)	<0.001	0.53 (0.44–0.65)	0.004

HAP, hepatoma arterial-embolization prognostic score; mHAP, modified hepatoma arterial-embolization prognostic score; PFS, progression-free survival.

^† p-value for comparing the C-index of ADMAN model and other prognostic model.

Bold values represent p-value < 0.05.